8-K: Alzamend Neuro Issues Common Stock from Preferred Share Conversion

Sentiment:

Equity Conversion Update 1 August 2025 4:30 PM

Alzamend Neuro, Inc. announced the issuance of 243,429 common shares through the conversion of Series B Convertible Preferred Stock, increasing total common shares outstanding to 3,139,861.

Capital raiseThe common shares issued were a result of the conversion of Series B Convertible Preferred Stock, which was originally issued in reliance upon the exemption from registration requirements under Section 4(a)(2) of the Securities Act, indicating a prior private placement capital raise.

Summary

Alzamend Neuro, Inc. issued an aggregate of 243,429 shares of common stock.
These common shares were issued between July 23, 2025, and July 30, 2025.
The issuance resulted from the conversion of approximately 564.76 shares of Series B Convertible Preferred Stock.
The common stock was issued in reliance upon the exemption from registration requirements under Section 4(a)(2) of the Securities Act.
As of July 30, 2025, the company had 3,139,861 shares of common stock outstanding.

Sentiment

Score: 5

Explanation: Neutral. The filing reports a routine conversion of preferred stock to common stock, which is a factual corporate action with no explicit positive or negative operational implications disclosed.

Negatives

Issuance of 243,429 common shares increases the total common shares outstanding, leading to potential dilution for existing common shareholders.

Future Outlook

No forward-looking statements or guidance are provided in this filing.

Industry Context

This filing details a specific corporate capital structure adjustment and does not provide broader industry context or trends.

Stakeholder Impact

Shareholders: Existing common shareholders may experience dilution due to the increase in the number of common shares outstanding.

Key Dates

Date	Description
2025-07-23	Start date of common stock issuance period from preferred stock conversion.
2025-07-30	End date of common stock issuance period from preferred stock conversion and date of common stock outstanding count.
2025-08-01	Date of report filing.

Recommendation

hold

The filing details a routine conversion of preferred stock into common stock, resulting in an increase in the total number of common shares outstanding. While this conversion leads to dilution for existing common shareholders, the filing does not provide new operational or financial performance data to warrant a change in investment thesis. Investors should monitor future filings for business performance updates.

Keywords

Common Stock, Preferred Stock Conversion, Equity Issuance, Shares Outstanding, SEC Filing, Form 8-K, Alzamend Neuro, ALZN, Section 4(a)(2)

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.